nitric oxide, x, 7, 14, 97, 100, 101, 103, 104, 105, 107, 110, 123, 128, 129, 130, 131, 132, 137, 138, 148, 149, 154, 160, 161, 164, 165, 249 nitric oxide synthase, 14, 103, 149 nitrogen, 103, 226, 230, 234, 253, 325 nitrogen compounds, 325 nitrosamines, 21 NMDA, 162 NMR, 256, 271, 285, 286, 289, 290, 291, 298, 299, 309, 312 NO synthase, 7 NOA, 89 nociception, 223 nociceptive, 223 nodulation, 327 noise, 258 non-insulin dependent diabetes, 174 non-invasive, xiii, 255, 256 non-small cell lung cancer, 45 nonsmokers, 23, 32, 47 non-steroidal anti-inflammatory drugs, 37, 99, 130, 135, 224 nontoxicity, xiv, 275 non-vascular, 68 noradrenaline, 107 norepinephrine, 107 norfloxacin, 328 normal, x, 12, 16, 17, 18, 19, 21, 46, 97, 102, 103, 112, 134, 160, 172, 179, 186, 231, 250 normalization, 258, 259 norms, 51 NOS, 7, 103 nose, 66 NSAIDs, x, 97, 98, 99, 102, 104, 105, 106, 109, 111, 112, 113, 114, 126 N-terminal, 107, 109, 133 nuclear, ix, 1, 3, 7, 36, 145, 149, 150, 165, 166, 220, 229, 232, 256 nuclear magnetic resonance, 145, 220, 256, 285 nuclear receptors, 3 nucleic acid, 8, 111 nucleus, 192, 230, 232 nuclides, 206 nutraceutical, 174, 177 nutrient, 2, 32, 142, 211, 318 nutrients, 13, 30, 31, 32, 101, 110, 304 nutrition, ix, xiii, 36, 46, 275 nutritional imbalance, 54 <strong>Index</strong> O 357 oat, 185 obese, 5 obesity, 4, 173, 174, 175, 176, 177, 181, 182, 187 observations, 14, 56, 102 occlusion, 159, 229 ODS, 144 <strong>of</strong>loxacin, 190 oil, 13, 15, 60, 65, 67, 84, 115, 134, 135, 146, 159, 208, 224, 236, 253, 324 oils, xi, xiii, 2, 68, 90, 96, 139, 140, 181, 187, 192, 247, 255, 316, 317, 323, 325 older people, 62 oleic acid, 194 oligomers, 311 oligosaccharide, 293, 309 oligosaccharides, 288, 291, 292, 293, 309, 310, 312 olive, 67, 177, 334 omega-3, 131, 182 oncology, 42 onion, 172, 177 online, 74, 258, 303 opioid, 223 opposition, 66 optical, 257, 259, 260, 266, 285, 288 optics, xiii, 255, 267 optimal health, 8 optimization, 142, 157, 259 oral, 14, 15, 17, 38, 40, 104, 105, 129, 169, 170, 172, 187, 222, 248, 324 oral hypoglycemic agents, 170, 172 organ, 190, 223, 224, 231 organic, ix, 21, 55, 66, 68, 95, 144, 177, 199, 220, 224, 283, 288, 306, 307, 317 organic compounds, 21, 95 organic solvent, 144, 283, 288 organic solvents, 144, 288 organism, 64, 127, 319 ornithine, 44 osmotic, 286 osmotic pressure, 286 OST, 177 ovary, 29 overlay, 319 overload, 61 ovulation, 224 oxidants, 17, 21 oxidation, xiv, 3, 8, 16, 17, 18, 21, 37, 44, 103, 146, 159, 174, 175, 234, 279, 281, 282, 297, 309
358 oxidative, 4, 8, 9, 10, 12, 13, 16, 17, 18, 32, 33, 34, 38, 43, 46, 47, 106, 131, 159, 214, 231, 234, 235 oxidative damage, 8, 10, 16, 32, 34, 43 oxidative stress, 8, 9, 12, 13, 17, 18, 33, 38, 106, 131, 235 oxide, xi, 7, 14, 97, 100, 101, 103, 104, 105, 107, 109, 110, 123, 128, 129, 130, 131, 132, 137, 138, 148, 149, 154, 160, 161, 164, 165, 247, 249, 288 oxygen, ix, 1, 3, 7, 8, 9, 12, 16, 17, 25, 39, 40, 44, 47, 99, 101, 102, 105, 109, 110, 134, 148, 162, 164, 226 oxygenation, 104 oxyradicals, 40 ozone, 9 p38, 151 p53, 32, 43, 164 PACE, 288, 292, 311 PAF, 249 pain, 27, 59, 61, 62, 66, 132, 133, 168, 248 palliative, 42 palpitations, 72 pancreas, 168, 172, 173 pancreatic, 168, 175, 176, 177, 178, 181, 185 pancreatitis, 166 paracrine, 103 paradoxical, 107 parallelism, 142 paralysis, 60 paramagnetic, 148 parameter, 286 paraoxonase, 40 parasite, 319, 331, 333, 336 parasitemia, 319 parasites, 67, 316, 319, 325, 330 parenchyma, 229, 232, 236, 246 parietal, 99 PARP, 151 partial least squares regression, 259 partial thromboplastin time, 276 particles, 22, 100, 110 pasta, 179, 186 Patent <strong>and</strong> Trademark Office, 39 pathogenesis, 12, 99, 105, 106, 109, 112, 127, 174 pathogenic, 61, 193, 276, 308, 316, 319 pathogenic agents, 61 pathogens, 100, 110, 325 pathology, 27, 215 P <strong>Index</strong> pathophysiological, 46 pathophysiology, 128 pathways, 10, 17, 25, 31, 32, 43, 107, 128, 130, 196, 230, 235 patients, 4, 6, 13, 18, 19, 20, 28, 29, 30, 33, 34, 36, 37, 41, 42, 44, 45, 135, 158, 170, 171, 172, 177, 179, 181, 182, 187, 190, 215, 276, 277, 316 PbS, 257 PC12 cells, 307 PCA, 258, 269, 271 PCR, 143, 258 PDI, 230 peanuts, 175, 182, 324 pectin, 302, 308, 311 peers, 168 PEF, 283 penicillin, 329, 336 pepsin, x, 97, 98, 99, 103, 128 peptic ulcer, 98, 99, 100, 134 peptic ulcer disease, 134 peptide, 107, 108, 110, 130, 132, 133, 134, 179, 186, 310, 322 peptides, 107, 322, 325, 333, 336 perception, 76 percolation, 144 perforation, 112 perfusion, 249 periodontal, 154, 165, 166 periodontal disease, 154, 166 peripheral blood, 133, 152, 223 peritoneal, 108, 162, 308 peritonitis, 106 permeability, xv, 102, 134, 197, 222, 315, 322, 326, 329, 334 permeation, 100, 283, 285 permit, 291, 330 peroxidation, 3, 8, 38, 148, 230, 237 peroxide, 307, 310 peroxynitrite, 161 pests, 225 Petri dish, 318 PGE, 102, 110, 125 P-glycoprotein, 276 pH, 99, 100, 144, 208, 229, 230, 265, 283, 295 phagocytic, 324 pharmaceutical, ix, xiii, xiv, 50, 66, 76, 98, 174, 217, 218, 235, 275, 296 pharmaceutical industry, xiv, 275 pharmaceuticals, 76 pharmacies, 75
- Page 2 and 3:
BIOTECHNOLOGY IN AGRICULTURE, INDUS
- Page 4:
Industrial Biotechnology Shara L. A
- Page 7 and 8:
Copyright © 2009 by Nova Science P
- Page 9 and 10:
viii Contents Chapter 8 Pharmacolog
- Page 11 and 12:
x Alejandro Varela and Jasiah Ibañ
- Page 13 and 14:
xii Alejandro Varela and Jasiah Iba
- Page 15 and 16:
xiv Alejandro Varela and Jasiah Iba
- Page 18 and 19:
In: Medicinal Plants: Classificatio
- Page 20 and 21:
Biological Effects of -Carotene acy
- Page 22 and 23:
Biological Effects of -Carotene cry
- Page 24 and 25:
Biological Effects of -Carotene ris
- Page 26 and 27:
Biological Effects of -Carotene Whe
- Page 28 and 29:
Biological Effects of -Carotene fla
- Page 30 and 31:
Biological Effects of -Carotene Pre
- Page 32 and 33:
Biological Effects of -Carotene A (
- Page 34 and 35:
Biological Effects of -Carotene As
- Page 36 and 37:
Biological Effects of -Carotene car
- Page 38 and 39:
Biological Effects of -Carotene res
- Page 40 and 41:
Biological Effects of -Carotene the
- Page 42 and 43:
Biological Effects of -Carotene cat
- Page 44 and 45:
Biological Effects of -Carotene mos
- Page 46 and 47:
Biological Effects of -Carotene dia
- Page 48 and 49:
Biological Effects of -Carotene veg
- Page 50 and 51:
Biological Effects of -Carotene .Su
- Page 52 and 53:
Biological Effects of -Carotene Bat
- Page 54 and 55:
Biological Effects of -Carotene Dah
- Page 56 and 57:
Biological Effects of -Carotene Hal
- Page 58 and 59:
Biological Effects of -Carotene Kva
- Page 60 and 61:
Biological Effects of -Carotene Osh
- Page 62 and 63:
Biological Effects of -Carotene San
- Page 64:
Biological Effects of -Carotene Van
- Page 67 and 68:
50 Gustavo J. Martínez, Mara Sato
- Page 69 and 70:
52 Gustavo J. Martínez, Mara Sato
- Page 71 and 72:
54 Gustavo J. Martínez, Mara Sato
- Page 73 and 74:
56 Gustavo J. Martínez, Mara Sato
- Page 75 and 76:
58 [2] Gustavo J. Martínez, Mara S
- Page 77 and 78:
60 Gustavo J. Martínez, Mara Sato
- Page 79 and 80:
62 Gustavo J. Martínez, Mara Sato
- Page 81 and 82:
64 Gustavo J. Martínez, Mara Sato
- Page 83 and 84:
66 Gustavo J. Martínez, Mara Sato
- Page 85 and 86:
68 Gustavo J. Martínez, Mara Sato
- Page 87 and 88:
70 Gustavo J. Martínez, Mara Sato
- Page 89 and 90:
Huperzia saururus (Lam.) Trevis. Mi
- Page 91 and 92:
74 Gustavo J. Martínez, Mara Sato
- Page 93 and 94:
76 Gustavo J. Martínez, Mara Sato
- Page 95 and 96:
PNEUMONOLOGY AND INFECTIOUS DISEASE
- Page 97 and 98:
80 Gustavo J. Martínez, Mara Sato
- Page 99 and 100:
82 Gustavo J. Martínez, Mara Sato
- Page 101 and 102:
84 Gustavo J. Martínez, Mara Sato
- Page 103 and 104:
86 Gustavo J. Martínez, Mara Sato
- Page 105 and 106:
88 Gustavo J. Martínez, Mara Sato
- Page 107 and 108:
90 Gustavo J. Martínez, Mara Sato
- Page 109 and 110:
92 Gustavo J. Martínez, Mara Sato
- Page 111 and 112:
94 Gustavo J. Martínez, Mara Sato
- Page 113 and 114:
96 Gustavo J. Martínez, Mara Sato
- Page 115 and 116:
98 Aracely E. Chávez-Piña and And
- Page 117 and 118:
100 Aracely E. Chávez-Piña and An
- Page 119 and 120:
102 Aracely E. Chávez-Piña and An
- Page 121 and 122:
104 Aracely E. Chávez-Piña and An
- Page 123 and 124:
106 Aracely E. Chávez-Piña and An
- Page 125 and 126:
108 Aracely E. Chávez-Piña and An
- Page 127 and 128:
110 Aracely E. Chávez-Piña and An
- Page 129 and 130:
112 Aracely E. Chávez-Piña and An
- Page 131 and 132:
114 Aracely E. Chávez-Piña and An
- Page 133 and 134:
116 Aracely E. Chávez-Piña and An
- Page 135 and 136:
118 HO HO HO HO HO HO OH OH M e Me
- Page 137 and 138:
120 Me Me OH Me O OH O O OH H Me OH
- Page 139 and 140:
122 HO HO HO Aracely E. Chávez-Pi
- Page 141 and 142:
124 Aracely E. Chávez-Piña and An
- Page 143 and 144:
126 Aracely E. Chávez-Piña and An
- Page 145 and 146:
128 Aracely E. Chávez-Piña and An
- Page 147 and 148:
130 Aracely E. Chávez-Piña and An
- Page 149 and 150:
132 Aracely E. Chávez-Piña and An
- Page 151 and 152:
134 Aracely E. Chávez-Piña and An
- Page 153 and 154:
136 Aracely E. Chávez-Piña and An
- Page 155 and 156:
138 Aracely E. Chávez-Piña and An
- Page 157 and 158:
140 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 159 and 160:
142 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 161 and 162:
144 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 163 and 164:
146 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 165 and 166:
148 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 167 and 168:
150 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 169 and 170:
152 6.4. Antibacterial Effects Hua-
- Page 171 and 172:
154 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 173 and 174:
156 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 175 and 176:
158 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 177 and 178:
160 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 179 and 180:
162 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 181 and 182:
164 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 183 and 184:
166 Hua-Bin Li, Dan Li, Ren-You Gan
- Page 185 and 186:
168 Vandana Gulati, Ian H. Harding
- Page 187 and 188:
170 Vandana Gulati, Ian H. Harding
- Page 189 and 190:
172 Vandana Gulati, Ian H. Harding
- Page 191 and 192:
174 Vandana Gulati, Ian H. Harding
- Page 193 and 194:
176 Vandana Gulati, Ian H. Harding
- Page 195 and 196:
178 Vandana Gulati, Ian H. Harding
- Page 197 and 198:
180 Vandana Gulati, Ian H. Harding
- Page 199 and 200:
182 Vandana Gulati, Ian H. Harding
- Page 201 and 202:
184 Vandana Gulati, Ian H. Harding
- Page 203 and 204:
186 Vandana Gulati, Ian H. Harding
- Page 206 and 207:
In: Medicinal Plants: Classificatio
- Page 208 and 209:
Biomolecules with Anti-Mycobacteria
- Page 210 and 211:
Biomolecules with Anti-Mycobacteria
- Page 212 and 213:
Biomolecules with Anti-Mycobacteria
- Page 214 and 215:
Biomolecules with Anti-Mycobacteria
- Page 216 and 217:
Biomolecules with Anti-Mycobacteria
- Page 218:
Biomolecules with Anti-Mycobacteria
- Page 221 and 222:
204 Chien-Yi Chen Ligusticum chuanx
- Page 223 and 224:
206 Chien-Yi Chen (IAEA 336), also
- Page 225 and 226:
208 Chien-Yi Chen 4. Results and Di
- Page 227 and 228:
210 4.3. Fresh Leaves and Stems Chi
- Page 229 and 230:
212 Chien-Yi Chen collected from na
- Page 231 and 232:
214 Chien-Yi Chen primary enzyme in
- Page 233 and 234:
216 Chien-Yi Chen [20] Liu SM, Chun
- Page 235 and 236:
218 S.M.M. Vasconcelos, J.E.R. Hon
- Page 237 and 238:
220 S.M.M. Vasconcelos, J.E.R. Hon
- Page 239 and 240:
222 S.M.M. Vasconcelos, J.E.R. Hon
- Page 241 and 242:
224 S.M.M. Vasconcelos, J.E.R. Hon
- Page 243 and 244:
226 S.M.M. Vasconcelos, J.E.R. Hon
- Page 245 and 246:
228 S.M.M. Vasconcelos, J.E.R. Hon
- Page 247 and 248:
230 S.M.M. Vasconcelos, J.E.R. Hon
- Page 249 and 250:
232 S.M.M. Vasconcelos, J.E.R. Hon
- Page 251 and 252:
234 S.M.M. Vasconcelos, J.E.R. Hon
- Page 253 and 254:
236 S.M.M. Vasconcelos, J.E.R. Hon
- Page 255 and 256:
238 S.M.M. Vasconcelos, J.E.R. Hon
- Page 257 and 258:
240 S.M.M. Vasconcelos, J.E.R. Hon
- Page 259 and 260:
242 S.M.M. Vasconcelos, J.E.R. Hon
- Page 261 and 262:
244 Sônia Sin Singer Brugiolo, Luc
- Page 263 and 264:
246 Sônia Sin Singer Brugiolo, Luc
- Page 265 and 266:
248 Sônia Sin Singer Brugiolo, Luc
- Page 267 and 268:
250 Sônia Sin Singer Brugiolo, Luc
- Page 269 and 270:
252 Sônia Sin Singer Brugiolo, Luc
- Page 271 and 272:
254 Sônia Sin Singer Brugiolo, Luc
- Page 273 and 274:
256 C.W. Huck and G.K. Bonn Keyword
- Page 275 and 276:
258 C.W. Huck and G.K. Bonn No addi
- Page 277 and 278:
260 C.W. Huck and G.K. Bonn The rob
- Page 279 and 280:
262 C.W. Huck and G.K. Bonn Validat
- Page 281 and 282:
264 Naphthodianthrones C.W. Huck an
- Page 283 and 284:
266 C.W. Huck and G.K. Bonn Figure
- Page 285 and 286:
268 C.W. Huck and G.K. Bonn Figure
- Page 287 and 288:
270 C.W. Huck and G.K. Bonn hierarc
- Page 289 and 290:
272 C.W. Huck and G.K. Bonn [17] Hu
- Page 292 and 293:
In: Medicinal Plants Classification
- Page 294 and 295:
What is the Future of Phytotherapy?
- Page 296 and 297:
In: Medicinal Plants Classification
- Page 298 and 299:
Quality Control of Polysaccharides
- Page 300 and 301:
Quality Control of Polysaccharides
- Page 302 and 303:
Quality Control of Polysaccharides
- Page 304 and 305:
Quality Control of Polysaccharides
- Page 306 and 307:
Quality Control of Polysaccharides
- Page 308 and 309:
Quality Control of Polysaccharides
- Page 310 and 311:
Quality Control of Polysaccharides
- Page 312 and 313:
Origins Targets Neisseria meningiti
- Page 314 and 315:
Quality Control of Polysaccharides
- Page 316 and 317:
Quality Control of Polysaccharides
- Page 318 and 319:
Quality Control of Polysaccharides
- Page 320 and 321:
Quality Control of Polysaccharides
- Page 322 and 323:
Quality Control of Polysaccharides
- Page 324 and 325: Quality Control of Polysaccharides
- Page 326 and 327: Quality Control of Polysaccharides
- Page 328 and 329: Quality Control of Polysaccharides
- Page 330: Quality Control of Polysaccharides
- Page 333 and 334: 316 Philippe N. Okusa, Caroline Ste
- Page 335 and 336: 318 Philippe N. Okusa, Caroline Ste
- Page 337 and 338: 320 2.7. General Toxicity Tests Phi
- Page 339 and 340: 322 Philippe N. Okusa, Caroline Ste
- Page 341 and 342: 324 Philippe N. Okusa, Caroline Ste
- Page 343 and 344: 326 Philippe N. Okusa, Caroline Ste
- Page 345 and 346: 328 Philippe N. Okusa, Caroline Ste
- Page 347 and 348: 330 Philippe N. Okusa, Caroline Ste
- Page 349 and 350: 332 Philippe N. Okusa, Caroline Ste
- Page 351 and 352: 334 Philippe N. Okusa, Caroline Ste
- Page 353 and 354: 336 Philippe N. Okusa, Caroline Ste
- Page 355 and 356: 338 age-related macular degeneratio
- Page 357 and 358: 340 B lymphocytes, 7 babies, 60, 62
- Page 359 and 360: 342 cell surface, 229 cellular adhe
- Page 361 and 362: 344 cultivation, 75, 76, 83, 85, 14
- Page 363 and 364: 346 embryonic stem cells, 47 emotio
- Page 365 and 366: 348 gas, xiii, 21, 104, 131, 145, 1
- Page 367 and 368: 350 high-performance liquid chromat
- Page 369 and 370: 352 institutions, 84 instruments, 2
- Page 371 and 372: 354 lung, ix, 1, 6, 16, 17, 22, 23,
- Page 373: 356 mucosa, x, 2, 19, 97, 98, 99, 1
- Page 377 and 378: 360 polyunsaturated fatty acids, 10
- Page 379 and 380: 362 Reserpine, 328 reservation, 143
- Page 381 and 382: 364 SPT, 135 squamous cell carcinom
- Page 383 and 384: 366 transcription, 8, 35, 152 trans